These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31857845)

  • 1. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.
    Karpov AS; Nieto-Oberhuber CM; Abrams T; Beng-Louka E; Blanco E; Chamoin S; Chene P; Dacquignies I; Daniel D; Dillon MP; Doumampouom-Metoul L; Drosos N; Fedoseev P; Furegati M; Granda B; Grotzfeld RM; Hess Clark S; Joly E; Jones D; Lacaud-Baumlin M; Lagasse-Guerro S; Lorenzana EG; Mallet W; Martyniuk P; Marzinzik AL; Mesrouze Y; Nocito S; Oei Y; Perruccio F; Piizzi G; Richard E; Rudewicz PJ; Schindler P; Velay M; Venstrom K; Wang P; Zurini M; Lafrance M
    ACS Med Chem Lett; 2019 Dec; 10(12):1674-1679. PubMed ID: 31857845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
    Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X
    Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digestion-Free Middle-Down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from Antibody-Drug Conjugates.
    Yuan J; Tan HY; Huang Y; Rosenbaum AI
    Anal Chem; 2024 Oct; 96(42):16475-16480. PubMed ID: 39298786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates.
    Karpov AS; Abrams T; Clark S; Raikar A; D'Alessio JA; Dillon MP; Gesner TG; Jones D; Lacaud M; Mallet W; Martyniuk P; Meredith E; Mohseni M; Nieto-Oberhuber CM; Palacios D; Perruccio F; Piizzi G; Zurini M; Bialucha CU
    ACS Med Chem Lett; 2018 Aug; 9(8):838-842. PubMed ID: 30128077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
    Böhnke N; Berger M; Griebenow N; Rottmann A; Erkelenz M; Hammer S; Berndt S; Günther J; Wengner AM; Stelte-Ludwig B; Mahlert C; Greven S; Dietz L; Jörißen H; Barak N; Bömer U; Hillig RC; Eberspaecher U; Weiske J; Giese A; Mumberg D; Nising CF; Weinmann H; Sommer A
    Bioconjug Chem; 2022 Jun; 33(6):1210-1221. PubMed ID: 35658441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfatase-cleavable linkers for antibody-drug conjugates.
    Bargh JD; Walsh SJ; Isidro-Llobet A; Omarjee S; Carroll JS; Spring DR
    Chem Sci; 2020 Jan; 11(9):2375-2380. PubMed ID: 34084399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
    Harel ET; Drake PM; Barfield RM; Lui I; Farr-Jones S; Van't Veer L; Gartner ZJ; Green EM; Lourenço AL; Cheng Y; Hann BC; Rabuka D; Craik CS
    Antibodies (Basel); 2019 Nov; 8(4):. PubMed ID: 31694242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer.
    Mckertish CM; Kayser V
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.